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1. Introduction
Posttraumatic stress disorder (PTSD) (ICD-10 codes: F43.1, F62.0; DSM-IV-TR code: 309.81)
[1, 2] is a complex severe and chronic psychiatric illness influenced by environmental and
genetic factors [3-10]. PTSD is an anxiety disorder developed in a person experiencing, wit‐
nessing, or learning about an extreme physically or psychologically distressing event, asso‐
ciated with unprecedented violence [11, 12]. Traumatic events that can trigger PTSD include
massacres, mass murder scenes, international, civil, political, ethnic and religious wars, gen‐
ocides, natural and man-made disasters, criminal assaults, serious accidents, terrorist at‐
tacks, incarceration, trafficking, rape and other types of sexual assaults [12-17], life
threatening illness and the sudden death of a loved one, serious medical illness, injury, sur‐
gery, hostage, kidnapping, difficult labors, etc [18-20]. Individuals who experience a trauma
of this nature may develop symptoms that fall into three distinct clusters: re-experiencing
phenomenon; avoidance and numbing; and autonomic hyperarousal. Symptoms usually be‐
gin within the first 3 months after the traumatic event and last for many years, although
there may be a delay of months, or even years, before symptoms appear. PTSD patients are
characterized by severe emotional state, sharp reduction in adaptive and information receiv‐
ing abilities. They usually remain out of society, become drug addicted, alcoholic and often
commit suicide [21-24]. Degrees of risk to develop PTSD from different traumatic events are
presented in table 1.
It was shown that 37% of Cambodian refugees, 86% of women refugees in Kabul and Paki‐
stan and 75% of Bosnian refugee women suffer from PTSD. In USA 60% of female rape sur‐
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vivors and 35% of UK adult rape victims are affected by PTSD. Similar to adults, some
children, who witness or experience traumatic events, develop PTSD. Thus, in the USA
90-100% of children, who witness a parental homicide or sexual assault, develop PTSD, and
in the UK 50% of sexually abused children are affected by this disorder [25-27].
Equally as staggering are statistics, which monitor the incidence of PTSD among combat
veterans. Here, 30% of the American Vietnam veterans and 56% of Australia’s Vietnam War
veterans, 10% of Desert Storm veterans, 31% of Australia’s Gulf War veterans, 6-11% of Af‐
ghanistan veterans and 12-20% of Iraq veterans in the US suffer from PTSD [25-28].
Statistical data also demonstrates that women are more than twice as likely to develop PTSD
as men. Available data suggests that about 8% of men and 20% of women go on to develop
PTSD [26, 29-31]. Is was also shown that PTSD is most often developed in representatives of
national minorities, people surviving stressful events at list once in their life, as well as in
people with low level of education, mental problems, having mentally ill family member or
experiencing lack of support from their family members or friends [26, 29-31]. Currently, for
about 7-8% of the USA population, 2-3% of the UK population, 6.4% of Australians and 3%
of Cambodians suffer from PTSD [26-28].
Traumatic event Degree of risk, %
Rape 49.0
Other types of sexual violence 23.7
Physical violence, severe beating 31.9
Accident and/or serious injuries 16.8-20.0
Stabbing, shooting 15.4
Sudden death of a family member or friend 14.3
Child's life-threatening illness 10.4
Murder, death or serious injury witness 7.3
Natural disasters
- hurricane
- tsunami
- earthquake (adults/youths)
2.0-3.8
30.0-50.0
32.0-60.0 / 26.0-95.0
Man-made disasters 29.0
Terrorist attacks 28.0
Table 1. Risk for developing PTSD depending on traumatic event [25-27]
In Armenia PTSD is quite common as well, and is basically found among the descendants of
Armenian Genocide victims, including current generation, combatants, refugees and victims
of earthquake [32-40]. Thus, according to Goenjian et al, 73% among 1988 Spitak Earthquake
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survivors developed PTSD 4.5 years after the disaster [36]. In general, 10% of the world pop‐
ulation is suffering from PTSD, and 70% is under the risk of developing PTSD [26-28].
Patients with PTSD have a reduced quality of life, an increased number of suicides and hos‐
pitalizations, high frequency of depressions, alcohol and drug abuse; social, family life and
work become impossible.
Molecular mechanisms of generation and development of PTSD and their relation to the
clinical psychopathologic criteria of this disorder are not clear yet. The lack of knowledge in
this field significantly limits the development of effective therapeutic approaches for treat‐
ment of PTSD-affected subjects and prevention of further complications.
2. Neuroendocrine alterations in PTSD
PTSD is characterized by the central and autonomic nervous systems hyperarousal that is
caused by functional changes in the limbic system, which is located between the brainstem
and the cerebral cortex and coordinates their activities. This part of the brain regulates sur‐
vival behaviors and emotional expression, being primarily concerned with tasks of survival
such as eating, sexual reproduction and the instinctive defenses of fight and flight. It also
plays a central role in memory processing. The hippocampus and amygdala, parts of the
limbic system, regulate learning, memory, and emotion. The amygdala is important for the
regulation of emotional memories, particularly for fear causing memories. It has been pro‐
ven that amygdala is activated in the extreme situations. The hippocampus, on the contrary,
is suppressed in these conditions. It has been shown that PTSD is characterized by function‐
al hyperactivity of the amygdala and hypoactivity of the hippocampus [41-43].
A number of data suggests that alterations in the hypothalamic-pituitary-adrenal (HPA) axis
and sympathoadrenal system (SAS) play a leading role in PTSD pathogenesis [13, 14, 44].
Thus, PTSD, as compared to norm, is characterized by low cortisol levels in plasma and sali‐
va [45], whereas elevated levels of dehydroepiandrosterone (DHEA) and DHEA-sulfate are
detected in this disorder [44-46]. Moreover, increased levels of corticotrophin realizing hor‐
mone positively correlated with the high levels of cortisol in cerebrospinal fluid of PTSD pa‐
tients were observed [47]. Also, PTSD is characterized by increased glucocorticoid receptor
sensitivity [48]. An increased levels of noradrenaline, neurotransmitter of central and pe‐
ripheral sympathetic (adrenergic) nervous system, were detected in the cerebrospinal fluid
of PTSD patients [49]. Noradrenaline is considered as one of the important mediators of cen‐
tral and peripheral autonomic stress response and has an important role in the regulation
process of emotional memory [50]. It was also shown that high levels of noradrenalinefof the
PTSD of the PTSD in urine positively correlate with the symptoms of PTSD [51]. In addition,
the increased levels of dopamine, another mediator of the sympathetic nervous system and
precursor of noradrenaline, were found in the blood and body fluids of PTSD-affected sub‐
jects [51-53].
There are several data indicating assumption that functional abnormalities in neuroendo‐
crine system detected in PTSD patients are conditioned by hereditary factors [54]. Thus, as it
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follows from table 2, PTSD is associated with the genetic mutations in a number of genes
encoding neurotransmitters and hormones, their biosynthesis enzymes, receptors and trans‐
porters. Interestingly, 6 of the candidate genes for PTSD showed in the table 1 belong to the
dopamine system. A positive association between the risk for development PTSD and TaqIA
polymorphism of the dopamine D2 receptor gene was found [55]. Also, positive association
was revealed between tandem repeat polymorphism of dopamine transporter gene and
PTSD [56] as well as between dopamine D4 transporter gene long allele and severity of
PTSD symptoms [57].
The γ-3 subunit of γ-aminobutyric acid, another mediator of nervous system, has also been
studied in PSTD patients. Patients heterozygous for this gene have a higher probability of
developing somatic symptoms of PTSD, sleeping disturbances, fair and depression than ho‐
mozygous patients [58]. The studies of serotonin transporter gene showed that PTSD pa‐
tients carrying one or two short alleles of this gene have a higher level of depression and
suicide compared to carriers of long allele, which has more transcriptional power [59, 60].
The association of the serotonin transporter repeat polymorphism with PTSD was also de‐
scribed [61-63]. Interestingly, recent study of 200 individuals from 12 multigenerational fam‐
ilies survived 1998 Spitak earthquake in Armenia demonstrated that PTSD is developing in
those individuals, who carry mutations of tryptophan hydroxylase 1 and 2, the rate-limiting
enzyme of serotonin biosynthesis [64].
Candidate gene Chromosomal mapping Source
Dopamine D2 receptor 11q23 [22, 55, 65]
Dopamine D4 receptor 11p15.5 [57]
Dopamine transporter type 1 5p15.3 [56, 66]
Serotonin transporter 17q11 [10, 60, 63, 67- 71]
Serotonin type-2A receptor 13q14-q21 [68]
Brain-derived neurotrophic factor 11p13 [72]
Neuropeptide Y 7p15.1 [73]
Glucocorticoid receptor 5q31.3 [74]
Dopamine beta-hydroxylase 9q34 [75]
Cannabinoid receptor 6q14-q15 [76]
γ-aminobutyric acid receptor (subunit α-2) 4p12 [77]
Catechol-O-methyltransferase 22q11 [78]
Tryptophan hydroxylase 1
Tryptophan hydroxylase 2
11p15.3-p.14
12q21.1
[64]
Table 2. PTSD-related changes in the neuroendocrine system
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3. Immune system alterations in PTSD
Promising studies suggest the involvement of alterations in the immune status [48, 79-86],
particularly low-grade inflammatory reactions, in the pathogenesis of PTSD [87-97]. Тhus,
PTSD patients are characterized by hyperactivation of lymphocytes [80] and increased levels
of lipopolysaccharide (LPS)-stimulated expression of interleukin (IL)-6, tumor necrosis fac‐
tor (TNF)-α, and interferon (IFN)-γ in immunocompetent cells [81, 82]. Segman et al detect‐
ed over-expression of immune response-related genes in monocytes of PTSD-affected
subjects [85]. Also, in chronic PTSD patients, as compared to norm, a decreased number of
T-killer cells (CD8+) [98, 99] and an increase number of T-helper cells (CD4+) [98, 100] has
been shown, whereas in PTSD patients immediately after a traumatic event a decreased
number of T-helper cells was detected [99]. A number of experimental data indicates that
natural killer cells’ cytotoxicity in PTSD is lower than in norm [97, 99, 101-104], while the
total number or these cells, as well as a number of CD16+ and CD56+ cells in their total popu‐
lation is higher than in norm [99, 104]. At the same time some studies show that natural kill‐
er cells’ cytotoxicity in PTSD patients is higher than in healthy subjects [105, 106]. The
analysis of the above mentioned data revealed altered cell-mediated immunity in PTSD pa‐
tients and demonstrates that depending on traumatic event, duration and stage of the ill‐
ness, these alterations may be either under- or over-represented [97, 107].
3.1. Cytokine network in PTSD
A number of studies have demonstrated changes in a functional state of cytokines and their
receptors, important mediators and regulators of the immune response in PTSD-affected
subjects. Here the increased blood levels of proinflammatory cytokines (e.g. IL-1β, IL-6,
TNF-α, INF-γ) and decreased levels of anti-inflammatory cytokines (e.g. IL-4) are detected
in chronic PTSD patients indicating the involvement of low-grade systemic inflammatory re‐
actions in PTSD pathogenesis (table 3).
In our own study the levels of proinflammatory and chemotactic cytokines IL-1β, IL-6, TNF-
α, IL-8 and MCP-1 in the blood serum of chronic PTSD patients (combat veterans) and age-
and sex-matched healthy subjects (HS; a control group) were determined using enzyme-
linked immunosorbent assay (ELISA). Assessment of possible correlation of the above
mentioned parameters with each other and with the expression of PTSD clinical symptoms
was also performed. The latest were evaluated using Structured Clinical Interview for the
DSM-IV Axis I Disorders (SCID PTSD module) [112] and Clinician-Administered PTSD
Scale (CAPS) [113]. In particular, we assessed correlation between the levels of cytokines
and the degree of expression of such PTSD clinical symptoms as persistent re-experiencing
of the traumatic event (B cluster), persistent avoidance of stimuli associated with the trauma
and emotional numbing (C cluster); persistent symptoms of increasing arousal (D cluster)
[2]. In table 4 brief descriptions of the study groups is given. Table 5 demonstrates the indi‐
vidual symptom clusters (B, C, and D criteria), and total CAPS scores of PTSD-affected sub‐
jects involved in our study.
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Chronic PTSD patients: group description Changes in the blood levels of cytokines
as compared to norm*
Source
Accidents survivors (n=13) ↑IL-1β, ↑IL-6, ↑TNF-α [89]
Accident survivors (n=86) ↑IL-1β [46]
Accidents survivors (n=14) ↑IL-1β, ↑TNF-α, ↓IL-4 [93]
Bosnian refugees (n=12) ↑IL-6 [108]
Combat veterans (n=19) ↑IL-1β, ↑IL-6, ↑TNF-α [87]
Combat veterans (n=11) ↑IL-6, ↑TNF-α [91]
Individuals abused in childhood (n=30) ↑INF-γ [109]
Individuals abused in childhood (n=177) ↑TNF-α , ↓IL-4 [110]
Individuals exposed to different traumatic events
(n=60)
↓IL-4 [97]
Individuals exposed to intimate partner violence
(n=62)
↑IL-6, ↑TNF-α, ↑INF-γ [111]
* - ↑ - above the norm; ↓ - below the norm.
Table 3. Changes in the blood levels of some cytokines in chronic PTSD patients
Data statistics include nonparametric Mann-Whitney U-test and correlation analysis with
calculation of Spearman’s rank correlation coefficient (Rs). Parts of this study have been
published [114, 115].
The results obtained indicated that PTSD, as compared to norm, is characterized by in‐
creased levels of the mentioned above cytokines (Table 6), which is consistent with reports
by other research groups (Table 3) [46, 87, 89, 91, 93, 108, 110, 111].
A significant correlation between the levels of IL-1β and IL-6 (Rs=0.45; p<0.003), as well as
between IL-1β and MCP-1 (Rs=0.3; p<0.03) in PTSD patients was revealed, whereas no sig‐
nificant correlation between the levels of cytokines was observed in control group. Also, a
significant positive correlation of IL-1β and IL-6 blood levels with PTSD symptoms within B,
C and D criteria (CAPS scores) was detected. Thus, levels of IL-1β positively correlated with
B frequency (Rs=0.004, р=0.007), C frequency, intensity, and frequency + intensity (Rs=0.4,
p=0.009; Rs=0.30, p=0.035, r=0.36, p<0.02, respectively), frequency of B, C and D (Rs =0.37,
p<0.02), total intensity of B, C and D (Rs=0.3, p<0.048) and total frequency + intensity of B, C
and D (Rs=0.3, p<0.03). Blood levels of IL-6 positively correlated with cluster B frequency
(Rs=0.3, p=0.048).
Our data provides further evidence on the association of chronic inflammation with PTSD
and clearly demonstrates the interrelation between the expression of PTSD symptoms and
inflammatory reactions. Alterations in the immune response in PTSD accompanied by low-
grade systemic inflammation aggravate disease course and severity and contribute to devel‐
opment of complications. Thus, PTSD is often associated with autoimmune and
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inflammatory disorders such as rheumatoid arthritis, psoriasis and inflammatory bowel dis‐
ease. Patients with PTSD are at a higher risk for diabetes mellitus and cardiovascular diseas‐
es (atherosclerosis, myocardial infarction) [116-123]. It is interesting that in peridontitis
patients with PTSD higher expression of inflammatory processes was obtained than in those
peridontitis patients, who were not affected by PTSD [88].
Study group PTSD HS
Total number (male/female) 120 (116/4) 80 (76/4)
Mean age (M±SD) 42 ± 11.3 39 ± 9.1
[Cortisol]* (M±SD), ng/ml 124 ± 47 145 ± 55
[DHEA]* (M±SD), ng/ml 13 ± 7 10 ± 5
[DHEA-sulfate]* (M±SD), μg/ml 1.8 ± 0.9 1.0 ± 0.5
* - measured in the blood serum
Table 4. Brief description of the study groups
Symptom clusters Parameters PTSD patients scores
B cluster Frequency (0-20) 11.8±3.98
Intensity (0-20) 11.6±3.46
Frequency + Intensity (0-40) 23.4±7.02
C cluster Frequency (0-28) 16.4±5.10
Intensity (0-28) 14.8±4.96
Frequency + Intensity (0-56) 31.2±9.85
D cluster Frequency (0-20) 13.5±3.07
Intensity (0-20) 12.2±2.52
Frequency + Intensity (0-40) 25.7±5.30
B+C+D (Total) Frequency (0-68) 41.7±9.85
Intensity (0-68) 38.6±9.18
Frequency + Intensity (0-136) 80.3±18.50
Table 5. The individual symptom clusters (B, C, and D criteria), total and overall CAPS scores (M±SD) of PTSD-affected
subjects (Score ranges are indicated in parenthesis)
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Study group Cytokine Level ( M ± SD), pg/ml P =
PTSD
IL-1β
8.2 ± 1.0
0.002
HS 5.1 ± 0.7
PTSD
IL-6
19.0 ± 2.5
0.025
HS 16.0 ± 2.3
PTSD
TNF-α
12.0 ± 1.6
0.049
HS 10.8 ± 1.4
PTSD
IL-8
11.5 ± 1.5
0.022
HS 10.1 ± 1.3
PTSD
MCP-1
223.3 ± 30.6
0.030
HS 187.2 ± 25.5
Table 6. Comparative analysis of the blood serum levels of proinflammatory and chemotactic cytokines in patients
with PTSD and HS
The pathological mechanisms of the development of inflammatory reactions in PTSD are not
clear. However, it is obvious that neuroendocrine and immune impairments in PTSD are in‐
terrelated. It is well-established fact that the immune system functional activity is regulated
by neurotransmitters and hormones, particularly those related to HPA axis and SAS. On the
other hand, immune system mediators and their receptors on the immunocompetent cells
may regulate the neuroendocrine system. In normal physiological conditions the immune,
endocrine and nervous systems maintain homeostasis by controlling each other, thus devel‐
oping adequate stress response [79, 124]. Changes in neuro-endocrine-immune interactions
(influenced by either environmental or genetic factors) may result to abnormal response to
stress and generation of PTSD. On the other hand, the action of cytokines, mediators of in‐
flammation, is tightly coupled with physiological and pathophysiological reactions of the
organism, and their important role is to coordinate the efforts of the immune, endocrine and
nervous systems during the stress response [125-128]. This may represent one of the possible
mechanisms responsible for increased cytokines levels and development of chronic inflam‐
matory reactions in PTSD, the disease characterized by neuroimmune and endocrine altera‐
tions [82, 86, 129]. It connection with this it has to be also mentioned that a number of recent
clinical and experimental data suggests the implication of low-grade systemic inflammatory
reactions accompanied by increase in cytokines levels in pathogenesis of many psychiatric
disorders [130-132].
3.2. The complement system in PTSD
The complement system is major effector of the immune response, which acts on the inter‐
face of innate and adaptive immunity, and is a key component and trigger of many immu‐
noregulatory mechanisms. Activation of the complement generates opsonins,
anaphylatoxins, and chemotaxins, mediators of inflammation and apoptosis (Figure 1)
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[133-135]. Changes in the functional activity of the complement cascade contribute to the
pathology of many human diseases [136-138], including mental disorders [139-144], and are
also detected during physiological stress [145-146]. The alterations in the complement cas‐
cade have been considered as indicator of the implication of inflammatory component in
disease etiology, pathogenesis and/or progression [136-138].
Figure 1. Complement activation pathways; C1Q, C1r, C1s – subunits of the complement C1 component; MBL - man‐
nan-binding lectin; MASP1 - MBL-associated serine peptidase 1; MASP2 - MBL-associated serine peptidase 2; FD - fac‐
tor D; FB - factor B; MAC – membrane attack complex.
The complement system with its central position in innate and adaptive immunity mediates
a variety of effector functions. It consists of more than 30 circulating proteins, cell surface
receptor and regulator proteins. It is a complex cascade involving proteolytic cleavage of se‐
rum glycoproteins often activated by cell receptors. This cascade ultimately results in induc‐
tion of the antibody responses, inflammation, phagocyte chemotaxis, and opsonization of
apoptotic and necrotic cells, facilitating their recognition, clearance, and lysis. Complement
exhibits three activation pathways - classical, alternative, and lectin, initiated via separate
mechanisms, and a single terminal pathway that results in a formation of the membrane at‐
tack complex (Figure 1) and subsequent cell lysis [133-135]. During the past decades it has
become evident that dysfunction of complement contributes to the pathology of many hu‐
man diseases [136-138], including mental disorders (schizophrenia, Alzheimer's disease,
Huntington's and Pick's diseases) [139-142], and is also detected during physiological stress
[145-146]. While, as it was already mentioned, PTSD-affected subjects showed a low-grade
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systemic proinflammatory state, the complement system in PTSD has been never studied be‐
fore.
In our study we assessed the functional activity of the complement cascade in PTSD by de‐
termining total hemolytic activities of its classical and alternative pathways, and hemolytic
activities of its individual components, C1, C2, C3, C4, factor B and factor D, in the blood
serum of chronic PTSD patients (combat veterans) and HS (tables 4, 5). C1, C2 and C4 are
main components of the classical pathway, factor B and factor D are essential components of
the alternative pathway, and C3 is the initial point for the alternative pathway and a con‐
verge point of all three complement activation pathways, starting up for the terminal path‐
way (Figure 1) [133-135]. In addition, correlation study between all measured parameters
was also performed. Hemolytic activities of the complement classical and alternative path‐
ways (CH50 and AH50, respectively) and of the complement components C1 (C1H50), C2
(C2H50), C3 (C3H50), C4 (C4H50), factor B (fBH50), and factor D (fDH50) in the blood se‐
rum of PTSD-affected and healthy subjects were measured by application of the earlier de‐
veloped methods [147, 148]. Data was analyzed by Student’s unpaired two-tailed t-test and
Pearson’s correlation analysis including calculation of relevant correlation coefficient (r).
Parts of this study have been published [149-152].
The results obtained are presented in table 7. According to the results obtained, mean values
of serum CH50, C1H50, C2H50 and C4H50 in PTSD patients were significantly 2.1, 1.34, 1.2
and 1.6 times significantly higher than in case of HS (p<0.05). On the contrary, mean values
of serum C3H50, AH50, fBH50, and fDH50 in PTSD patients were 1.5, 1.7, 1.6, and 2.3 times
significantly lower as compared to HS (p<0.05). Correlation analysis also demonstrated that
in PTSD affected subjects C1H50 is significantly correlated with C2H50 (r=-0.375, p<0.04),
C3H50 is significantly correlated with C1H50, C2H50 and C4H50 and AH50 (r=0.53, p<0.037;
r=0.72, p=0.002; r=0.5, p=0.05; r=0.57, p=0.027, respectively). No significant correlation be‐
tween the above-mentioned parameters was detected in the HS group (p>0.05).
Hemolytic activity, U/ml* PTSD (M ± SD) HS (M ± SD) P =
CH50 375.00 ± 164.40 176.00 ± 88.50 0.0002
C1H50 92.21 ± 52.83 68.80 ± 37.39 0.0400
C2H50 67.60 ± 35.10 58.80 ± 8.80 0.0450
C3H50 37.57 ± 16.26 55.92 ± 28.60 0.0300
C4H50 60.10 ± 28.42 36.64 ± 20.31 0.0300
AH50 52.30 ± 18.17 87.60 ± 9.80 0.0001
fBH50 40.80 ± 14.30 65.2 ± 34.1 0.0200
fBH50 71.70 ± 15.98 163.70 ± 70.58 0.0010
* - one unit (U) of hemolytic activity is defined as an amount of serum that causes a 50% hemol‐
ysis of erythrocytes in a reaction mixture.
Table 7. Functional state of the complement system in PTSD patients and HS
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The results obtained in our study clearly demonstrated that pathogenesis of PTSD is charac‐
terized by complement dysfunction including hyperactivation state of the complement clas‐
sical pathway and hypoactivation state of the complement alternative pathway. The
alternative pathway of complement is activated following spontaneous hydrolysis of the
thioester bond of native C3, resulting into binding of factor B, which is cleaved by factor D,
generating the efficient alternative pathway C3 convertase C3bBb. Multifunctional comple‐
ment protein C3 is the initial point of the alternative pathway, and, at the same time, a con‐
verge point of all three complement activation pathways, i.e. starting point for the terminal
pathway [93, 135, 153]. Hypoactivation state of the alternative pathway together with de‐
creased activity of the complement C3 component, detected in PTSD affected subjects, prob‐
ably reflects depletion of the C3 component due to its overutilization through the terminal
pathway. This suggestion is convenient with correlation data indicating positive correlation
between CH50 and C3H50 and absence of any correlation between AH50 and fBH50, and
AH50 and fDH50 in PTSD affected subjects. Thus, it is obvious that the alternative pathway
in PTSD is suppressed on the initial stage of its activation, and that PTSD is also character‐
ized by overactivated terminal complement pathway. On the other hand, absence of correla‐
tion between AH50 and CH50 suggests that alterations in activities of the classical and the
alternative complement pathways in PTSD are not interdependent.
As it was mentioned above, alterations in the complement cascade have been considered as
indicator of the implication of inflammatory component in disease etiology, pathogenesis
and/or progression [136-138]. Our study demonstrates that PTSD is associated with dysfunc‐
tion of the complement system, and reveals the altered chains of the complement cascade.
The results obtained provide further evidence on the involvement of the inflammatory com‐
ponent in pathogenesis of PTSD. Here we hypothesize that neuroendocrine mechanisms re‐
lated to PTSD modulating the immune function might affect the initial steps in the
inflammatory cascade and thus influence alterations in the functional activity of the major
mediator of the inflammatory response, the complement system. However, to address mo‐
lecular mechanisms responsible for the complement dysfunction in PTSD as well as their
role in PTSD pathogenesis further studies are needed.
3.3. Immune complexes in PTSD
Formation of immune complexes (IC) is a normal physiological reaction of organism to for‐
eign or autoantigen. IC may interact with both humoral and cellular components of the im‐
mune recognition system, activate the complement cascade, and thus affect the immune
response on multiple levels [154-156]. In healthy conditions IC are easily eliminating from
circulation through complement deposition, followed by their opsonization, phagocytosis,
and further processing by proteases [154, 156-158]. In pathologic conditions inappropriate
clearance or deposition of IC result in increased levels of IC in circulation. Circulating IC
may deposit in endothelial or vascular structures provoking prolonged inflammatory re‐
sponse by permanent activation of the complement cascade through the classical pathway,
generation of cytotoxic agents and tissue damage [159-163]. Deposition of IC is a prominent
feature of many diseases [162-164] including those characterized by low-grade systemic in‐
Alterations in the Immune Response, Apoptosis and Synaptic Plasticity in Posttraumatic Stress Disorder
http://dx.doi.org/10.5772/52693
115
flammation, such as schizophrenia [144], diabetes mellitus [165, 166], ischemic and hemor‐
rhagic stroke [167-169].
In our own study we, for the first time, determined total levels of IC as well as the levels of
IC containing activation products of the complement system, C1q- and C3d-IC, in the blood
serum of chronic PTSD patients (combat veterans) and HS. Brief characteristic of study
groups is given in tables 3, 4. Total levels of IC were measured by a previously published
spectrophotometric method and expressed in absorbency units at 280 nm (A280) [167]; C1q-
and C3d-IC were measured by ELISA. Data was analyzed by Student’s unpaired two-tailed
t-test and Pearson’s correlation analysis including calculation of relevant correlation coeffi‐
cient (r). Parts of this study have been published [149, 150, 170].
According to the results obtained, PTSD-patients comparing to HS are characterized by sig‐
nificantly increased serum levels of total IC as well as C1q- and C3d-IC. Thus, the mean lev‐
el of total IC in PTSD patients was 1.5 times higher than in HS (p=0.0055) and the levels of
C1q-IC, and C3d-IC were 1.7 (p=0.024) and 1.6 times (p=0.0004), respectively, higher as com‐
pared to HS. The results obtained are summarized in table 8.
[IC], (M±SD) Study group P =
PTSD HS
[Total IC], A280 0.18 ± 0.1 0.12 ± 0.03 0.0055
[C1q-IC], μg/ml (M±SD) 44.6 ± 37.67 26.28 ± 16.33 0.024
[C3d-IC], μg/ml (M±SD) 29.75 ± 21.91 18.67 ± 8.22 0.0004
Table 8. Serum levels of the total IC, C1q-IC and C3d-IC in PTSD patients and HS
In addition, a significant positive correlation between the levels of C1q- and C3d-IC (r=0.32;
p<0.03) was detected in PTSD patients affected subjects. Moreover, in patients with PTSD
we also revealed a significant positive correlation between the total levels of IC and hemo‐
lytic activity of the classical complement pathway. This finding indicates that increased total
levels of IC in circulation may be responsible for hyperactivation of the classical comple‐
ment cascade detected in PTSD [149-152, 170].
The increased blood levels of C1q-IC in PTSD provide further evidence for this suggestion.
C1q-IC contain C1q subunit of the complement protein C1, and binding of IC to C1q ini‐
tiates activation of the classical complement cascade (Figure 1) [133-135].
C3d-IC contain activation cleavage products of the complement С3 protein, opsonins C3b,
iC3b and C3dg. These entire products contain "d"-terminal fragment of the С3 polypeptide
chain. In healthy conditions C3d-IC are eliminated from the blood through interaction with
the complement receptors on monocytes, neutrophils and erythrocytes. Monocytes and neu‐
trophils subject C3d-IC to phagocytosis, and erythrocytes transfer them to liver and spleen
for further phagocytosis by macrophages. Increased blood levels of C3d-IC suggest about al‐
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terations in mechanisms responsible for their recognition and clearance by the above men‐
tioned cells. High levels of C3d-IC result in hyper-production of antibodies, because binding
of C3d-IC to type-2 complement receptors (СR2) on the surface of B-lymphocytes induces
the production of immunoglobulins by these cells [154, 156-158]. Therefore, our results indi‐
cate that PTSD is characterized by altered mechanisms of IC recognition and clearance,
which may be responsible for the increased classical pathway functional activity, chronic ac‐
tivation of the immune system and systemic inflammation.
3.4. Interrelation between inflammatory response, apoptosis and synaptic plasticity in
PTSD
As it was already mentioned, the molecular pathomechanisms responsible for development
of inflammatory reactions in PTSD are yet unclear, which limits the progress in develop‐
ment of the efficient measures of PTSD rehabilitation therapy and prevention of its compli‐
cations. On the other hand, it is known that apoptosis plays an important role in down-
regulation of the inflammatory response by reducing the lifespan of activated
immunocompetent cells [171-173]. Therefore, we proposed that one of the factors contribu‐
ting to PTSD-associated inflammation may be apoptotic dysfunction as it was observed in
case of other disorders like familial Mediterranean fever [174], inflammatory bowel disease
[175], systemic inflammatory response syndrome [176], pulmonary hemorrhage or endotox‐
emia [177], etc.
On the third though, apoptosis is considered as the important regulator of synaptic plastici‐
ty. Apoptotic alterations have a significant input in synaptic dysfunction and lead to
changes in structural and functional integrity of neuronal circuits [178-180]. Therefore, apop‐
tosis may be also responsible for altered synaptic plasticity in PTSD [181] resulting in cogni‐
tive impairments and development of depressions in PTSD affected subjects [182-184].
To check our hypotheses, in the blood serum of patients with PTSD, in comparison to HS
the levels of marker proteins for apoptosis and synaptic plasticity, annexin-А5 [185] and
complexin-2 [186], respectively, and the inflammatory marker, TNF-α, were determined by
ELISA. The analysis of correlation between these parameters was performed. Brief charac‐
teristic of study groups is given in tables 4, 5. Data statistics include nonparametric Mann-
Whitney U-test and correlation analysis with calculation of Spearman’s rank correlation
coefficient (Rs). The results presented below have not been published yet.
According to the results obtained, the levels of both annexin-А5 and complexin-2 in PTSD
patients were significantly 2.34 (p=0.0001) and 1.21 (p=0.03) times, respectively, lower than
in case of HS (table 9). In addition, a significant positive correlation between the levels of
annexin-А5 and complexin-2 (Rs=0.38, p=0.045), on the one hand, and a significant negative
correlation between the levels of annexin-А5 and the increased levels of TNF-α (Rs= -0.35,
р=0.047), on the other hand, were detected in PTSD.
No statistical significant correlation was observed between these parameters in case of HS.
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Study group [Annexin-A5], ng/ml P = [Complexin-2], pg/ml P =
PTSD 0.82 ± 0.70
0.0001
121.5 ± 41.20
0.03
HS 1.92 ± 1.05 146.9 ± 56.64
Table 9. The levels of annexin A5 and complexin-2 (M ± SD) in PTSD patients and HS
Our results demonstrated that PTSD is characterized by the decreased blood levels of the
apoptotic marker circulating annexin A5 indicating association of apoptosis hypofunction
with this disorder.
On the base of the results obtained we suggest that PTSD is characterized by low rate of
apoptosis associated with the defects in synaptic plasticity and that anomalous apoptosis
may also represent one of the factors responsible for development of PTSD-associated
chronic inflammation. This suggestion is confirmed by recent findings indicating the in‐
creased levels of leukocytes in the blood of chronic PTSD patients [48, 93, 94].
4. Conclusion
The results presented in this chapter provide evidence on implication of altered immune re‐
sponse, particularly low-grade systemic inflammation, in pathogenesis of PTSD.
In particular, we demonstrated that chronic PTSD is characterized by increased blood levels
of proinflammatory and chemotactic cytokines, IL-1β, IL-6, TNF-α and MCP-1, IL-8, respec‐
tively. Here, the increased levels of IL-1β and IL-6 positively correlate with the degree of ex‐
pression of clinically significant symptoms of this disease, which indicate that these
cytokines may be considered as new therapeutic targets for PTSD treatment. In addition, we
demonstrated that chronic PTSD is characterized by altered mechanisms of IC recognition
and clearance resulting in the increased levels of total IC, as well as C1q-IC and C3d-IC in
circulation. Furthermore, our results showed that chronic PTSD is characterized by altera‐
tions in functional activity of the complement pathways including hyperactivation state of
the classical and terminal pathways, hypoactivation state of the alternative pathway and de‐
ficiency of the C3 complement protein. Here, the data obtained suggests that hyperactiva‐
tion of the classical complement pathway is induced by the increased levels of IC,
particularly C1q-IC, in circulation. Regarding the alternative pathway, our results clearly
demonstrated that it is suppressed at the initial stage of activation and that decreased activi‐
ty of this pathway in PTSD is stipulated by decreased activities of its components, factor B
and factor D, and deficiency of the protein C3, a key component of the complement cascade.
In summery, we concluded that changes in functional activities of the proinflammatory and
chemotactic cytokines and complement cascade, as well as disturbances in the IC recogni‐
tion and clearance processes are implicated in pathogenesis of chronic PTSD.
Another important conclusion that can be drawn from the results of our study is that patho‐
genesis of chronic PTSD is characterized by low rate of apoptosis associated with the defects
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in synaptic plasticity, and that anomalous apoptosis may represent one of the factors re‐
sponsible for development of PTSD-associated chronic inflammation.
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